Biological Evaluation of Novel Synthesized 2, 5-disubstituted-1, 3, 4-oxadiazole derivatives
Abstract
Synthesis of a series of various 2, 5-disubstituted-1, 3, 4-oxadiazole derivatives (7a-7v) have been done previously. These novel synthesized derivatives (7a-7v) have been tested for their antibacterial activity against Gram +ve S. aureus and Gram -ve E. Coli bacterias by broth dilution method. A comparative study has been done for all derivatives. Based on the visual turbidity, the MIC of the evaluated molecules has been studied, the evaluation concentration was used single therefore, the exact MIC could not determined and results are represented in less than and more than based on growth of microorganism. To get more exact MIC of the tested molecules need to be evaluated at low concentration. Further testing for all compounds at lower concentrations is required to compare their activity with standard Streptomycin at its MIC to get exact MIC the synthesized compounds.
Previously novel synthesized derivatives are; 2-(phenoxymethyl)-5-phenyl-1, 3, 4-oxadiazole (7a), 4-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)aniline (7b), 3-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl) aniline (7c), 2-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7d), 2, 4-dinitro-6-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7e), 2-(4-(methylthio)benzyl)-5-(phenoxymethyl)-1,3,4-oxadiazole (7f), 2-((2, 4-dichlorophenoxy) methyl)-5-phenyl-1,3,4-oxadiazole (7g), 4-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7h), 3-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7i), 2-(5-((2, 4-dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl)phenol (7j), 2-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)-4,6-dinitrophenol (7k), 2-((2,4-dichlorophenoxy) methyl)-5-(4-(methylthio)benzyl)-1,3,4-oxadiazole (7l), (Z)-2-((2, 4-dichlorophenoxy) methyl)-5-styryl-1,3,4-oxadiazole (7m), (S)-4-(2-(5-((2,4-dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl)propyl)phenol (7n), 2-((4-nitrophenoxy) methyl)-5-phenyl-1, 3, 4-oxadiazole (7o), 4-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)aniline (7p), 3-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)aniline (7q), 2-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)phenol (7r), 2, 4-dinitro-6-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)phenol (7s), 2-(4-(methylthio) benzyl)-5-((4-nitrophenoxy) methyl)-1,3,4-oxadiazole (7t), (Z)-2-((4-nitrophenoxy)methyl)-5-styryl-1,3,4-oxadiazole (7u) and 5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazole-2-thiol (7v).
DOI
https://doi.org/10.22270/jddt.v9i4-A.3522Published


How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).